The Institute for Clinical and Economic Review (ICER) has weighed in on Eli Lilly’s type 2 diabetes drug candidate tirzepatide, saying payers should consider broadening coverage to GLP-1 RAs and SGLT-2 inhibitors like tirzepatide for diabetes type 2 patients with cardiovascular or renal disease — but only at a cost of $5,500 to $5,700 per year.
Source: Drug Industry Daily